pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Vaccines · news · pharmadog
← back to Vaccines
News · Vaccines
311
stories
16d
Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch
biopharma dive
16d
The main therapy used for children with autism faces changes under Medicaid
stat
16d
Gilead’s Yeztugo beats forecasts as HIV PrEP franchise exceeds $1B
endpoints
17d
Ebola kills 1,700 in eastern Congo as the fastest-growing outbreak surges
stat
17d
Pfizer expands multibillion-dollar cost-cutting plan
biopharma dive
17d
BioNTech cuts sales forecast on slumping demand for COVID-19 vaccine
biospace
17d
Pfizer cuts $2.5B more across R&D, manufacturing in ongoing restructure
biospace
17d
Trans federal employees sue over revoked health coverage
stat
18d
RFK Jr. interview sparks corrections on vaccines, pandemics and measles
endpoints
18d
BioNTech taps Sobi executive Oelkers as its next CEO
biopharma dive
18d
STAT+: BioNTech names Guido Oelkers its new CEO
stat
21d
Moderna's norovirus vaccine readout is delayed because of too few infections
endpoints
21d
Moderna maintains 10% growth target despite Phase 3 norovirus miss
biospace
21d
Opinion: What a recent op-ed got wrong about our Covid study
stat
22d
Key Senate panel backs Trump’s picks for CDC, pandemic preparedness
stat
22d
Sanofi’s new CEO wants more ‘realistic view’ of Phase 3 go/no-go decisions
biospace
22d
Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues
fiercebiotech
22d
US releases $600M in funding for global health group Gavi
endpoints
23d
FDA Licenses First-Ever Freeze-Dried Plasma Product in the U.S.
fda press
23d
Earnings roundup: Biogen’s ‘resiliency,’ AstraZeneca’s growth pitch and GSK’s oncology push
biopharma dive
23d
Six key issues we’re watching at Fauci’s hearing
stat
24d
STAT+: GSK lays out plans to cut costs, pursue more late-stage drug trials
stat
24d
GSK unveils 3-year cost-saving plan to fund late-stage R&D, move research HQ to AZ's backyard
fiercebiotech
25d
Opinion: How midwives like me can help fight medical misinformation
stat
28d
There are already more U.S. measles cases this year than in all of 2025
stat
28d
Novo asks court to block Lilly ads; Merck strikes HIV PrEP deal
endpoints
29d
Chutes & Ladders—Biogen R&D vet gets in Formation
fiercebiotech
29d
From Abu Dhabi to Brazil, every region is vying for the ‘new emerging economy’ of biotech
fiercebiotech
29d
STAT+: Vote on key federal health nominee delayed amid questions over vaccine views
stat
29d
Expect a clash at today’s FDA peptide panel
stat
← prev
page 4 of 11
next →
